A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization.
We sought to describe the effect of a Helicobacter pylori eradication strategy on health care costs among a cohort of health maintenance organization (HMO) members with peptic ulcer disease (PUD).
Patients were identified from an outpatient diagnosis database and verified at chart review to have new-onset PUD by upper endoscopy or upper gastrointestinal radiographic series.
Health plan registration and accounting databases were used to track costs over 12 months after initial diagnosis.
Costs were analyzed separately for an initial 2-month interval and a 10-month follow-up period.
Inpatient and pharmacy costs are those directly attributable to PUD (either a PUD-related discharge diagnosis or an antiulcer medication prescription).
Outpatient costs are total costs
All cost differences were adjusted for age and gender.
Twenty-seven of 93 patients meeting selection criteria received H. pylori treatment.
During the 2-month treatment window, adjusted PUD-related inpatient costs were higher for the H. pylon treated group (difference, $234.00/person), whereas total outpatient costs and PUD-related pharmacy costs were similar.
During the 10-month follow-up period, PUD-related inpatient and pharmacy adjusted costs were similar, but adjusted outpatient costs in the H. pylori treated group were lower than in the untreated group (difference, $508.00/person).
Total adjusted follow-up period costs were $555.00/person less in the H. (...)
Mots-clés Pascal : Ulcère, Gastroduodénal, Etiopathogénie, Gastrite, Bactériose, Infection, Helicobacter pylori, Spirillaceae, Spirillales, Bactérie, Eradication, Coût, Etude comparative, Homme, Appareil digestif pathologie, Estomac pathologie, Intestin pathologie, Economie santé
Mots-clés Pascal anglais : Ulcer, Gastroduodenal, Etiopathogenesis, Gastritis, Bacteriosis, Infection, Helicobacter pylori, Spirillaceae, Spirillales, Bacteria, Eradication, Costs, Comparative study, Human, Digestive diseases, Gastric disease, Intestinal disease, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0296438
Code Inist : 002B13B03. Création : 27/11/1998.